Biotech Firm Eyeing First in Man Studies

LAS VEGAS, NV / ACCESSWIRE / August 31, 2016 / The progress biotechnology companies have been making towards fighting cancer, Peter Evans of the UK Times, sees a number of companies expanding their portfolio with potential new drug combinations that may “finally beat cancer”.

Larger drug makers are scouring development, preclinical and clinical biotechs looking for emerging treatments and drugs that could in concert with their IPs could beat cancer.

This could have significant implications for innovative new approaches, like Propanc Health Group Corporation’s lead product, PRP. The Company announced earlier this summer that they have engaged the services of two advisory firms in North America, Maxim Group LLC and Partner International Inc., to explore potential strategic partnering opportunities for the company’s PRP treatment.

Propanc Health Group Corporation (PPCH), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers.

The Company aims to fast track the development of proenzyme related oncology products into clinical trials initially for pancreatic and ovarian cancers, followed by colorectal cancer. According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020.

Propanc (PPCH) has just announced significant progress of development activities ahead of the First-In-Man studies for their PRP treatment.

First-In-Man studies are exactly what they sound like, the first studies on human subjects, in some circles it is referred to as Phase 0.

Why is this big?

Because this means PPCH is close to becoming a clinical stage biotechnology company. This is a major milestone on the horizon. There are several markers in between which should make for exciting announcement and could help bring this oversold company back to its 2015 highs.

Point is, Propanc is sitting at a bottom, and has a litany of positive announcements ahead potentially. Now would be a great time to buy your tickets for what should be a fun ride up heading into next year’s trials.

Lpath, Inc. (LPTN) has been climbing since the company said it was awarded a government grant to develop its pain treatment, Lpathomab.

Arrowhead Pharmaceuticals, Inc. (ARWR) was initiated with Buy rating and $15 (112% upside) price target by Cantor Fitzgerald.

Reata Pharmaceuticals, Inc. (RETA) has seen a ton of insider buying recently which could be a harbinger for some near term success.

Regenxbio, Inc. (RGNX) has been on a roll since releasing their financials a couple weeks ago, and show no signs of slowing down.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.

SOURCE: ACR Communication, LLC

ReleaseID: 444576